Schizophrenia/Psychosis

Evidence review focuses on bipolar disorder, psychosis, and major depression.

How is this new drug going to help in the treatment of agitation in patients with schizophrenia or bipolar disorder?

How can looking at the suffering of patients with schizophrenia through a psychodynamic lens help clinicians develop effective interventions and treatment plans?

The FDA has approved dexmedetomidine sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Predicting mania versus psychosis: Researchers performed a retrospective study of prodromal symptoms, risk factors, and vulnerability markers in first-episode mania and psychosis.

Patients with bipolar I disorder and other mental illnesses may be at increased risk for COVID-19 infection.

Are you taking your medication? Researchers performed a nationwide register-based study of primary antipsychotic nonadherence in schizophrenia.

Findings from a recent study can help clinicians optimize antipsychotic dosing during acute illness exacerbations.

In this CME article, familiarize yourself with various pharmacokinetic, pharmacodynamic, and patient-specific factors to review to develop a successful cross-titration plan from one antipsychotic to another.

A new meta-analysis identifies target for improved care in patients with schizophrenia.

Thinking about sex and sleep in schizophrenia: Researchers performed a large cross-sectional study of sex differences in insomnia and cognition in chronic schizophrenia.

Have you had difficulty with differential diagnosis when patients have manic symptoms and psychosis? One doctor discusses the related DSM-5 criteria changes and some of their implications for psychopharmacology.

The glass is half full: reflections on where we are and hope for where we are heading in psychiatry.

Here's why the RAISE study is important and what you need to know to help patients.

The supplemental new drug application of brexpiprazole for the treatment of schizophrenia in pediatric patients aged 13 to 17 received FDA approval.

Sanjai Rao, MD, DFAPA, and Kimberly Garcia, DNP, CRNP provide some advice to clinicians on explaining schizophrenia to patients and caregivers to achieve understanding and therapy adherence.

Is cannabis’ effect on schizophrenia being downplayed?

Dr. Sanjai Rao and nurse practitioner Kimberly Garcia explain the barriers patients face in getting treatment with long-acting injectables and how COVID-19 has affected patient care.

Experts discuss the advantages of using the longest-acting injection formulation to treat schizophrenia, and whether there’s a need to discuss LAIs with patients from onset of illness.

Kimberly Garcia, DNP, CRNP, and Sanjai Rao, MD, DFAPA, review the administration frequencies of long acting injectables risperidone, aripiprazole, and paliperidone.

Sanjai Rao, MD, DFAPA, starts a conversation on how to discuss long acting injectables with patients and how to best transition from an oral medication.

Nurse Practitioner Kimberly Garcia and Dr. Sanjai Rao have a discussion on how they treat schizophrenia and highlight the considerations of prescribing long-acting injectables.

Key opinion leaders comment on how to monitor and increase patient treatment adherence to prevent relapse.

Sanjai Rao, MD, DFAPA, and Kimberly Garcia, DNP, CRNP, discuss how practitioners diagnose a schizophrenia relapse, and how to discuss relapse with patients.